CD8A and melanoma: In this context, SLAMF6 (signaling lymphocytic activation molecule family-6) is raising particular interest since it was identified as a favorable target for augmenting the functionality of CD8+ T cells against melanoma cells, both in vitro and in vivo [28,29].